Regents of The University of California Has $98,000 Stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Regents of The University of California trimmed its stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 98.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,633 shares of the company’s stock after selling 944,324 shares during the period. Tenaya Therapeutics comprises about 0.0% of Regents of The University of California’s investment portfolio, making the stock its 28th biggest position. Regents of The University of California’s holdings in Tenaya Therapeutics were worth $98,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in TNYA. Raymond James & Associates acquired a new position in Tenaya Therapeutics in the 2nd quarter valued at approximately $59,000. Balyasny Asset Management LLC bought a new stake in shares of Tenaya Therapeutics during the third quarter valued at approximately $29,000. Millennium Management LLC acquired a new position in shares of Tenaya Therapeutics in the second quarter valued at $65,000. California State Teachers Retirement System boosted its stake in Tenaya Therapeutics by 62.2% during the first quarter. California State Teachers Retirement System now owns 12,208 shares of the company’s stock worth $144,000 after buying an additional 4,682 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Tenaya Therapeutics in the 4th quarter valued at $25,000. Institutional investors own 70.22% of the company’s stock.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ TNYA traded down $0.05 during mid-day trading on Tuesday, hitting $1.83. 30,278 shares of the stock were exchanged, compared to its average volume of 441,918. Tenaya Therapeutics, Inc. has a twelve month low of $1.64 and a twelve month high of $8.09. The stock’s fifty day simple moving average is $2.31 and its two-hundred day simple moving average is $4.42. The company has a market cap of $124.58 million, a P/E ratio of -1.00 and a beta of 2.29.

Insider Buying and Selling

In other Tenaya Therapeutics news, insider Timothy Hoey sold 7,243 shares of Tenaya Therapeutics stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $4.26, for a total value of $30,855.18. Following the completion of the transaction, the insider now owns 247,396 shares in the company, valued at approximately $1,053,906.96. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 33.83% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

TNYA has been the topic of several recent research reports. Chardan Capital reiterated a “buy” rating and set a $23.00 target price on shares of Tenaya Therapeutics in a research report on Monday, August 14th. Lifesci Capital reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a report on Tuesday, August 8th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Monday, October 9th. Morgan Stanley boosted their price target on Tenaya Therapeutics from $13.00 to $14.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. Finally, Canaccord Genuity Group lowered their price target on Tenaya Therapeutics from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, August 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $18.00.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy.